Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is the most common form of diabetes, characterized by insulin resistance together with a relative, progressive failure of the pancreas to secrete enough insulin to compensate. It usually develops in adulthood against a background of overweight, physical inactivity, and genetic susceptibility, though it increasingly appears in younger people.

Definition

Type 2 diabetes mellitus is a form of diabetes characterized by insulin resistance combined with a relative deficiency of insulin secretion, leading to chronic hyperglycaemia that typically develops gradually.

Scope

This topic covers the pathophysiology of insulin resistance and beta-cell dysfunction, the clinical and epidemiological features of type 2 diabetes, and its relationship to prevention and long-term outcomes. It is framed as a reference clinical entity for understanding mechanism, classification, and the evidence base; it does not provide dosing or individualized treatment advice.

Core questions

• How do insulin resistance and beta-cell dysfunction combine to cause type 2 diabetes?
• What risk factors drive its development?
• Can progression from prediabetes to type 2 diabetes be prevented?
• How does glycaemic control relate to long-term complication risk?

Key concepts

• Insulin resistance
• Relative insulin deficiency
• Progressive beta-cell dysfunction
• Prediabetes and impaired glucose tolerance
• Obesity and lifestyle risk factors
• Legacy effect of early glycaemic control

Mechanisms

Type 2 diabetes develops when target tissues — muscle, liver, and adipose — become resistant to insulin's action while the pancreatic beta cells progressively fail to secrete enough insulin to overcome that resistance. Early on, compensatory hyperinsulinaemia can maintain near-normal glucose, but as beta-cell function declines, hyperglycaemia emerges and worsens. Insulin resistance is closely tied to excess adiposity, inactivity, and genetic predisposition, and the relentless, progressive nature of beta-cell decline explains why glucose control tends to deteriorate over time. This combination of impaired insulin action and inadequate secretion distinguishes it mechanistically from the absolute insulin deficiency of type 1 diabetes.

Clinical relevance

Type 2 diabetes is a leading global driver of cardiovascular, renal, and other chronic disease and a major public-health priority, making its mechanisms and prevention central to internal medicine. This entry presents pathophysiology, classification, and evidence for reference; it does not provide treatment regimens or individualized recommendations.

Epidemiology

Type 2 diabetes accounts for the large majority of all diabetes cases worldwide, and its prevalence has risen steeply with increasing obesity, ageing populations, and urbanization. It long carried the label adult-onset diabetes, but rising rates in children and adolescents have eroded that distinction.

Evidence & guidelines

The UK Prospective Diabetes Study showed that intensive glucose control reduces complication risk in type 2 diabetes, and its ten-year post-trial follow-up demonstrated a durable legacy effect of early control. The Diabetes Prevention Program established that lifestyle intervention or metformin can reduce progression from prediabetes to type 2 diabetes. Classification and diagnostic criteria are maintained in professional Standards of Care.

History

Type 2 diabetes was historically termed non-insulin-dependent or adult-onset diabetes. Landmark trials — the UK Prospective Diabetes Study on glucose control and the Diabetes Prevention Program on prevention — defined the modern evidence base linking glycaemic management and lifestyle to outcomes.

Seminal works

• chatterjee-2017
• ukpds33-1998
• holman-2008
• dpp-2002

Frequently asked questions

What is the core defect in type 2 diabetes?

It combines insulin resistance in target tissues with a progressive, relative failure of the pancreas to secrete enough insulin to compensate, producing chronic hyperglycaemia.

Can type 2 diabetes be prevented?

Trial evidence such as the Diabetes Prevention Program shows that lifestyle intervention or metformin can reduce progression from prediabetes to type 2 diabetes at the population level; this is general evidence, not individual medical advice.